# Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

> **NCT03094156** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 39 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIA 6-512
- **DRUG:** Madopar® 250
- **DRUG:** Comtan®

## Key facts

- **NCT ID:** NCT03094156
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-26
- **Primary completion:** 2006-07-11
- **Final completion:** 2006-07-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03094156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03094156, "Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03094156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*